Gene therapy for cancer treatment: past, present and future.

The broad field of gene therapy promises a number of innovative treatments that are likely to become important in preventing deaths from cancer. In this review, we discuss the history, highlights and future of three different gene therapy treatment approaches: immunotherapy, oncolytic virotherapy and gene transfer. Immunotherapy uses genetically modified cells and viral particles to stimulate the immune system to destroy cancer cells. Recent clinical trials of second and third generation vaccines have shown encouraging results with a wide range of cancers, including lung cancer, pancreatic cancer, prostate cancer and malignant melanoma. Oncolytic virotherapy, which uses viral particles that replicate within the cancer cell to cause cell death, is an emerging treatment modality that shows great promise, particularly with metastatic cancers. Initial phase I trials for several vectors have generated excitement over the potential power of this technique. Gene transfer is a new treatment modality that introduces new genes into a cancerous cell or the surrounding tissue to cause cell death or slow the growth of the cancer. This treatment technique is very flexible, and a wide range of genes and vectors are being used in clinical trials with successful outcomes. As these therapies mature, they may be used alone or in combination with current treatments to help make cancer a manageable disease.

[1]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[2]  C. Rudin,et al.  An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Schlom,et al.  TRICOM vector based cancer vaccines. , 2006, Current pharmaceutical design.

[4]  Sam S. Yoon,et al.  An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  D. Burgess,et al.  DNA-based therapeutics and DNA delivery systems: A comprehensive review , 2005, The AAPS Journal.

[6]  E. Jaffee,et al.  Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. , 2005, Cancer research.

[7]  S. Rabkin,et al.  Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. , 2005, Cancer research.

[8]  Leslie L Robison,et al.  Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Gehan,et al.  Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Jarnagin,et al.  Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses , 2000, Journal of Gastrointestinal Surgery.

[11]  J. Marshall,et al.  Costimulatory molecules as adjuvants for immunotherapy. , 2006, Frontiers in bioscience : a journal and virtual library.

[12]  A. Mackiewicz,et al.  Cancer Immunotherapy Using Cells Modified with Cytokine Genes , 2022 .

[13]  G. Demers,et al.  Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy. , 2003, Cancer research.

[14]  S. Ylä-Herttuala,et al.  AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  M. Hitt,et al.  Transcriptionally targeted adenovirus vectors. , 2005, Current gene therapy.

[16]  Hui Wang,et al.  Recent advances in experimental molecular therapeutics for malignant gliomas. , 2004, Current medicinal chemistry. Anti-cancer agents.

[17]  K. Tanabe,et al.  Viral Oncolysis for Malignant Liver Tumors , 2003, Annals of Surgical Oncology.

[18]  H. J. Baker,et al.  A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Yuan Zhang,et al.  Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  M. Dobbelstein Viruses in therapy--royal road or dead end? , 2003, Virus research.

[21]  Zhao-hui Peng,et al.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. , 2005, Human gene therapy.

[22]  R. Hruban,et al.  A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas , 2007 .

[23]  J. Nemunaitis GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[24]  F. Khuri,et al.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.

[25]  J. Nemunaitis,et al.  A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the baylor experience) , 2000, Annals of Surgical Oncology.

[26]  J. Roth,et al.  Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. , 2001, Seminars in oncology.

[27]  T. Thompson In situ gene therapy for prostate cancer. , 1999, Oncology research.

[28]  R. Martuza,et al.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.

[29]  A. Mackiewicz,et al.  Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer , 2001, Expert opinion on biological therapy.

[30]  F. Hall,et al.  Nanotechnology blooms, at last (Review). , 2005, Oncology reports.

[31]  Deborah Schrag,et al.  Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. , 2005, Journal of the National Cancer Institute.

[32]  D. Brough,et al.  TNFerade Biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene , 2002, Cancer Gene Therapy.

[33]  L. Looi,et al.  p53: an overview of over two decades of study. , 2001, The Malaysian journal of pathology.

[34]  T. Kikuchi Genetically modified dendritic cells for therapeutic immunity. , 2006, The Tohoku journal of experimental medicine.

[35]  N. Gordon,et al.  The challenges of bringing autologous HSP-based vaccines to commercial reality. , 2004, Methods.

[36]  S. Paul,et al.  Gene-based vaccines and immunotherapeutics , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Mulligan,et al.  The basic science of gene therapy. , 1993, Science.

[38]  H. Kaufman,et al.  Development of the PANVAC™-VF vaccine for pancreatic cancer , 2006, Expert review of vaccines.

[39]  J. Prieto,et al.  Gene therapy of liver diseases , 2004, Expert opinion on biological therapy.

[40]  J. Gu,et al.  Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  R. Warren,et al.  Intravascular adenoviral agents in cancer patients: Lessons from clinical trials , 2002, Cancer Gene Therapy.

[42]  R. Weichselbaum,et al.  TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D. Largaespada,et al.  Sleeping beauty transposon-mediated gene therapy for prolonged expression. , 2005, Advances in genetics.

[44]  J. Schlom,et al.  Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. , 2002, Cancer research.

[45]  K. Delman,et al.  Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer , 2002, Cancer Gene Therapy.

[46]  Yuan Zhang,et al.  Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  B. Sangro,et al.  Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. , 2003, Current gene therapy.

[48]  K. Tanabe,et al.  Viral oncolysis. , 2002, The oncologist.

[49]  R. Figlin,et al.  Phase I Trial of Antigen-Specific Gene Therapy Using a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in MUC-1-Positive Patients With Advanced Prostate Cancer , 2004, Journal of immunotherapy.

[50]  A. Schambach,et al.  Tumor cells escape suicide gene therapy by genetic and epigenetic instability. , 2004, Blood.

[51]  A. Armstrong,et al.  Science, medicine, and the future: Cellular immunotherapy for cancer. , 2001, BMJ.

[52]  B. Fox,et al.  Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer , 2006, Cancer Gene Therapy.

[53]  Lawrence M Wein,et al.  Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. , 2003, Cancer research.

[54]  R. Weichselbaum,et al.  A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities , 2004, Clinical Cancer Research.

[55]  S. Yla-Herttuala,et al.  Gene therapy for malignant glioma: current clinical status. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  F. McCormick,et al.  Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. , 2005, Cancer cell.

[57]  H. Pandha,et al.  Gene therapy for pancreatic cancer. , 1998, Italian journal of gastroenterology and hepatology.

[58]  P. Scardino,et al.  Intravesical oncolytic viral therapy using attenuated, replication‐competent, herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  N. Senzer,et al.  TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor α, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up , 2005, Annals of Surgical Oncology.

[60]  Adam Bagg,et al.  Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.

[61]  V. Margulis,et al.  Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants. , 2005, Urology.

[62]  D. Largaespada,et al.  Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[63]  P. Claudio,et al.  Gene therapy for lung cancer: practice and promise. , 2004, Annali italiani di chirurgia.

[64]  F. Hall,et al.  First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. , 2004, International journal of oncology.